Cepheid (NASDAQ:CPHD)

CAPS Rating: 3 out of 5

A molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the Clinical Molecular Diagnostic, Industrial and Biothreat markets.

Recs

1
Player Avatar KatWoman50 (< 20) Submitted: 7/29/2008 10:56:57 AM : Outperform Start Price: $17.20 CPHD Score: +76.40

Genetic analysis for diagnostic, industrial and biothreat markets. Picked up from Penny after 30% drop on earnings report. Slowdown in biothreat business leading drop but core staph test is solid and stock should come back now that it's out ot such high prices.

Featured Broker Partners


Advertisement